FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinatan	D C	20540	
Nashington,	D.C.	20049	

STATEMENT	OF	CHAN	GES	IN RE	NEFIC	IAI C	WNFR

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Linynsky Laura A</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Pediatrix Medical Group, Inc. [MD]								ck all app	,	ng Per	son(s) to Is:				
(Last)	(Fir	est) (M	/liddle)			3. Date of Earliest Transaction (Month/Day/Year) 05/09/2024								Office below	r (give title		Other (s below)	pecify	
1301 CO	NCORD T	ERRACE			4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) SUNRIS	E FL	3	3323										X	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(Sta	ate) (Z	Zip)		Rul	e 10	)b5-	1(c)	Trans	sact	ion Indi	catio	on						
						X Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See I													
		Table	I - Noi	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
Date			2. Transac Date (Month/Da	Execution Date,		Date,	Transaction Disposed Code (Instr. 5)		es Acquired (A) Of (D) (Instr. 3, 4			and Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D) Pr		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 05			05/09/2	/2024		<b>A</b> <sup>(1)</sup>		18,360	A	<b>A</b>	\$ <mark>0</mark>	37	37,805		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)		Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)				9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y   G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er					

## Explanation of Responses:

1. Restricted shares granted pursupant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 9, 2025.

/s/ Mary Ann E. Moore, Attorney-in-Fact

05/13/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.